FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
The Adipotide peptide is a synthetic peptidomimetic built from two functional parts: a homing motif that recognizes a marker on the vasculature of adipose tissue, and a proapoptotic domain that disrupts mitochondrial membranes. That two-domain design, a targeting address joined to a proapoptotic payload, is what makes Adipotide a distinct research tool in the study of targeted delivery and programmed cell death.
This article describes the structure of Adipotide, the homing-and-apoptosis mechanism it is studied for, how it sits within the broader metabolic-research catalog, and how the material is verified.
Research Snapshot
- Adipotide is a synthetic peptidomimetic with the molecular formula C111H206N36O28S2 and a molecular weight of approximately 2,557.2 g/mol. Its sequence is H-Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D(KLAKLAK)2.
- It is a two-domain molecule: a cyclic homing motif (stabilized by a disulfide bridge) that targets prohibitin, a marker associated with the vasculature of white adipose tissue, joined to a D(KLAKLAK)2 proapoptotic domain.
- The proapoptotic domain is a well-studied sequence that disrupts mitochondrial membranes and triggers apoptosis once it is delivered inside a targeted cell (Ellerby et al., 1999).
- The molecule incorporates D-amino acids and disulfide bridges specifically to resist proteolytic degradation and hold its structure under laboratory conditions, which is what makes it usable as a research tool.
- Pure Health Peptides supplies Adipotide as a lyophilized Vial, part of the wider catalog. Every lot is finished and tested in the US, routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
Introduction
Most research peptides act by engaging a receptor. Adipotide belongs to a different and smaller category: the targeted proapoptotic peptidomimetics, molecules designed to carry a cell-killing payload to a specific address and release it only there. The concept comes out of vascular-targeting research, where short homing motifs are used to direct a molecule to a particular tissue’s blood supply (Arap et al., 1998).
Adipotide is the catalog’s example of that design applied to adipose tissue vasculature. This article stays with the molecule and the preclinical research built on it: the two-domain structure, the homing-and-apoptosis mechanism, its place among the metabolic-research compounds, and the verification chain underneath the material.
It describes findings in preclinical and in vitro systems and holds to research-use framing throughout, with no extension to applied use.
The Adipotide Peptide: A Two-Domain Peptidomimetic
Adipotide’s structure is best read as two joined parts. The first is the homing motif, the cyclic Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys sequence, closed into a loop by a disulfide bridge between its two cysteines. This loop is what gives the molecule its address: it recognizes prohibitin, a protein marker associated with the endothelium of white adipose tissue vasculature (Mishra et al., 2006). The second part is the D(KLAKLAK)2 domain, a proapoptotic sequence written in D-amino acids.
Joining the two is the whole design. On its own, the KLAKLAK-type domain does not readily cross cell membranes, so it stays inert; the homing motif is what carries it to the targeted vasculature and allows it inside. The D-amino acids and disulfide bridges are there for stability, helping the peptidomimetic resist degradation in experimental conditions.
As a defined synthetic sequence, its identity is confirmed by mass spectrometry against its theoretical mass, the basis of lot-level verification.
The Homing-and-Apoptosis Mechanism
The mechanism Adipotide is studied for follows directly from its two domains. The homing motif localizes the molecule to the prohibitin-marked vasculature, and once the proapoptotic domain reaches the interior of a targeted endothelial cell, it disrupts the mitochondrial membrane and initiates apoptosis, the cell’s programmed death pathway (Ellerby et al., 1999). The targeting is what confines that effect to the intended cells rather than acting broadly.
This makes Adipotide a research model for two things at once: targeted delivery, the use of a homing motif to reach a specific vasculature, and mitochondrially-triggered apoptosis, the payload’s mode of action. Both are studied strictly in the preclinical and in vitro terms the literature uses.
The appropriate framing throughout is the molecular mechanism, not any applied result.
Adipotide in the Metabolic-Research Toolkit
Adipotide sits within the metabolic-research corner of the catalog, though its mechanism is unlike its neighbors, which is exactly what makes it a useful contrast. The small-molecule metabolic compounds SLU-PP-332 and 5-Amino-1MQ act on metabolic enzymes and receptors, and the mitochondrial-derived peptide MOTS-c works through mitochondrial signaling; each is covered in its own article (SLU-PP-332, 5-Amino-1MQ, MOTS-c).
Against that backdrop Adipotide is the outlier: not a signaling molecule at all, but a targeted proapoptotic peptidomimetic. Holding it alongside the signaling compounds gives a research program a mechanistically distinct tool, targeted delivery plus apoptosis rather than pathway modulation.
It is supplied as a lyophilized vial and is a distinct tool rather than a substitute for any of them.
Verification
Underneath the compound is the verification chain. Pure Health Peptides does not manufacture the material; production is sourced from qualified third-party manufacturers, and the material is finished and tested in the US. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner, and each qualified lot’s Certificate of Analysis is published in the COA Library, in the vial section, retrievable by batch ID.
For a lyophilized vialed peptide the appropriate panel extends beyond identity, purity, and quantity to include endotoxin and microbial limits, because contamination can enter downstream of synthesis through handling, lyophilization, vial filling, storage, and transit.
The Testing Process page documents how that verification runs, and the Manufacturing Process page covers where the material comes from. The guide to reading a Certificate of Analysis walks through the panel field by field.
Where Adipotide Sits in Targeted-Delivery Research
For researchers studying targeted delivery and programmed cell death, Adipotide is a specific and well-characterized tool: a two-domain peptidomimetic that pairs a vasculature-homing motif with a proapoptotic payload. Its research value rests on that modular design, an address joined to an effector, which makes it a clean model for how targeting and apoptosis can be combined in a single molecule.
As research on homing motifs and targeted proapoptotic peptides continues, Adipotide remains a well-defined reference compound, and it holds a distinct place in the metabolic-research corner of the catalog.
Frequently Asked Questions
What is the Adipotide peptide?
Adipotide is a synthetic peptidomimetic (molecular formula C111H206N36O28S2, molecular weight approximately 2,557.2 g/mol, sequence H-CKGGRAKDCGG-D(KLAKLAK)2) built from a vasculature-homing motif joined to a proapoptotic domain.
How is Adipotide structured?
As two parts: a cyclic, disulfide-bridged homing motif that targets prohibitin on adipose tissue vasculature, and a D(KLAKLAK)2 proapoptotic domain. D-amino acids and disulfide bridges are included for stability.
What is Adipotide studied for in research?
Two linked mechanisms: targeted delivery via its homing motif, and mitochondrially-triggered apoptosis via its proapoptotic domain, both in preclinical and in vitro systems.
Why does Adipotide use D-amino acids?
D-amino acids resist proteolytic degradation, which helps the peptidomimetic hold its structure and remain intact under laboratory conditions.
What carrier format is Adipotide available in, and how is it verified?
A lyophilized vial. Every lot is finished and tested in the US and routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Ellerby HM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nature Medicine, 1999;5(9):1032-1038. https://doi.org/10.1038/12469
- Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998;279(5349):377-380. https://doi.org/10.1126/science.279.5349.377
- Mishra S, Murphy LC, Murphy LJ. The Prohibitins: emerging roles in diverse functions. Journal of Cellular and Molecular Medicine, 2006;10(2):353-363. https://doi.org/10.1111/j.1582-4934.2006.tb00404.x
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
